Navigation Links
Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
Date:5/9/2011

ry.htm">electroporation device in a randomized, placebo-controlled, double-blind Phase II clinical study. We believe that these newly reported Phase I data showing long term persistence of antigen-specific T cells further support our confidence and  optimism for ultimately meeting the primary endpoint of this Phase II efficacy study: the clearance of CIN 2/3 lesions, measured at month 9, after three vaccinations at months 0, 1, and 3," concluded Dr. Kim.  

This recently initiated Phase II study will enroll 148 patients with CIN 2/3 or CIN 3 at approximately 25 study centers in the US, Korea, South Africa, Australia, and Canada. The study will also assess humoral and cell mediated immune responses to VGX-3100 in blood samples taken prior to the first vaccine dose and periodically thereafter. Cervical samples will be analyzed for evidence of immune responses in the cervix at baseline and subsequent intervals. Subjects will also be monitored for tolerability and safety.

The clinical trial protocol, HPV-003, is available at: http://clinicaltrials.gov/ct2/show/NCT01304524?term=NCT01304524&rank=1.

About Cervical Dysplasias/Cancers

Human papillomavirus (HPV) is the causative agent responsible for most cases of cervical cancer. At any given time, approximately 10% of women worldwide are infected with HPV. While roughly 70% of HPV infections are cleared by the body on its own, persistent HPV can lead to dysplasia, or premalignant changes in cells, of the cervix. Researchers have estimated the global prevalence of clinically pre-cancerous HPV infections at between 28 and 40 million. Persistent dysplasias may then progress to cancer. Every year, 510,000 cases of cervical cancer are diagnosed worldwide, and about 288,000 of the afflicted women, primarily in developing countries, die.

Preventive vaccines such as GARDASIL® and
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Inovio Pharmaceuticals Enters Phase II Clinical Trial with SynCon™ DNA Vaccine for Cervical Dysplasia Caused by HPV
2. Inovio Pharmaceuticals Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease
3. Inovio Pharmaceuticals to Present at 13th Annual BIO CEO & Investor Conference
4. Vanda Pharmaceuticals Reports First Quarter 2011 Results
5. MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results
6. Anadys Pharmaceuticals to Report First Quarter 2011 Financial Results
7. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
8. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
9. Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
10. Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings
11. Auxilium Pharmaceuticals to Announce First Quarter 2011 Results and Conduct Conference Call on Monday, May 9, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Pipette.com has added the ... their comprehensive portfolio of Eppendorf products. , The Eppendorf ... a Centrifuge 5424/5424 R and receive the following:, ... Research plus or Eppendorf Reference 2 , ...
(Date:1/22/2015)... Selexis SA, a serial innovation company with proven ... for drug discovery to commercial manufacturing, announced today all ... Sequencing (NGS) data packages. The NGS analysis of ... the integrity of the gene, validation of the left ...
(Date:1/22/2015)... Jan. 22. 2015  Varian Medical Systems (NYSE: VAR ... honored for its commitment to sustainability with inclusion on a ... the highest ranked healthcare equipment company among the Corporate Knights ... World Economic Forum at Davos, Switzerland . ...
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... (NYSE: MDT ) has submitted a pre-market ... (FDA) for the use of Medtronic,s SynchroMed ® ... catheter) for use with United Therapeutics, Remodulin ® ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... Open SurgeriesANDOVER, Mass., May 20 Smith & Nephew,s ... today announced the launch of the BICEPTOR Tenodesis (TEEN-oh-DEE-sis) ... the shoulder. Smith & Nephew Endoscopy,s BICEPTOR Tenodesis System ... biceps tendon to the humerus, or upper arm bone, ...
... NHL and ALL Highlighted at the 14th Congress ... in Breast Cancer to Be Presented at the ... May 20 Micromet, Inc. (Nasdaq: ... antibodies for the treatment of cancer, inflammation and ...
... Pharmaceuticals, Inc. (NASDAQ: ANPI , TSX: ... Scientific Corporation (NYSE: BSX ) has ... Stent System in select markets worldwide. The TAXUS ... engineered specifically for coronary stent applications and represents ...
Cached Biology Technology:Smith & Nephew Endoscopy Launches the BICEPTOR(TM) Tenodesis System, the First All-Arthroscopic Procedure for Biceps Tendon Repair 2Smith & Nephew Endoscopy Launches the BICEPTOR(TM) Tenodesis System, the First All-Arthroscopic Procedure for Biceps Tendon Repair 3Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO 2Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO 3Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO 4Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO 5Angiotech's corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent 2Angiotech's corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent 3Angiotech's corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent 4Angiotech's corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent 5
(Date:1/22/2015)... Infinisource has launched its new NXG series of time clocks ... a higher standard for collecting attendance and labor data and ... installation, touch screen interface and seamless connection to cloud-based iSolved, ... solution for the small to mid-size employer. The ...
(Date:12/22/2014)... , Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, announces ... Apollo Robbins for the 2015 International CES debut of ... Robbins will be at the NXT-ID booth January 6th ...
(Date:12/22/2014)... Dec. 22, 2014  The 2014 Holiday Season may be ... Market Intelligence reports that the long anticipated floodgates for ... intensifying demand for smart phones, tablets, and wearable mobile ... of 2.5 billion users with nearly 4.8 billion biometric ...
Breaking Biology News(10 mins):Infinisource's NXG series sets new time clock standard 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2
... WI, August 16th, 2010 - Fields amended with ... according to studies by USDA-Agricultural Research Service (ARS) ... about the agricultural pollutants that can build up ... nearby streams and rivers. Poultry producers ...
... be the cause of some of the most repugnant smells ... life forms actually has a sense of smell of its ... discovered for the first time that bacteria have a molecular ... as ammonia. Published today in Biotechnology Journal , their ...
... Man,s best friend might just be treated like any other ... David Blouin, assistant professor of the Department of Sociology and ... think of animals as children tend to have a city ... is not uncommon in rural areas," Blouin said, "which makes ...
Cached Biology News:Arsenic in field runoff linked to poultry litter 2Bacteria breakthrough is heaven scent 2Dogs' family status depends on family's locale 2
...
Request Info...
... This DuoSet ELISA Development kit contains the ... sandwich ELISAs to measure natural and recombinant ... and serum. Each kit contains sufficient materials ... plates, provided that the following conditions are ...
Conjugation services for Antibodies, Proteins, Oligos, Peptides, Beads, bioconjugation, antibody-oligonucleotide, LNA peptide, LNA protein, LNA antibody, HRP, Alkaline phosphatase, phycoerythrin, FIT...
Biology Products: